• U.S. Health Approves World's First Respiratory Syncytial Virus Vaccine
  • Q&A What is bronchiolitis: symptoms, causes and treatment

The European Commission has authorized the sale of the Arexvy vaccine against respiratory syncytial virus (RSV), responsible for bronchiolitis that kills thousands of people per year, announced a statement from British pharmaceutical giant GSK released Wednesday in London.

The authorization concerns people over the age of 60, GSK's statement said. The vaccine had already received a first marketing authorization on May 3, 2023 in the United States.

The European Medicines Agency (EMA) was in favour of authorisation last month, but the Commission's final decision had not yet arrived.

"This is the first time that an RSV vaccine has received marketing authorization in Europe," GSK said.

Find out more

ICU.

A three-month-old baby dies in Salamanca from bronchiolitis

  • Writing: F. R. / R. G. Valladolid

A three-month-old baby dies in Salamanca from bronchiolitis

Diseases.

Having had RSV bronchiolitis before age 3 could increase asthma risk by 2.5

  • Writing: EUROPA PRESS Madrid

Having had RSV bronchiolitis before age 3 could increase asthma risk by 2.5

Vaccinations are scheduled to begin in the fall, he added.

Each year, the virus generates in Europe "more than 270,000 hospitalizations and about 20,000 deaths during hospitalization" in older people, said the pharmaceutical company.

RSV is a widespread and contagious virus that usually causes mild cold-like symptoms.

But it can be serious for young children and adults, as well as for people with previous pathologies or weak immune systems.

In severe cases, it can cause pneumonia or bronchiolitis, inflammation in small airways of the lungs.

  • Vaccines

According to the criteria of The Trust Project

Learn more